IDEAS home Printed from https://ideas.repec.org/f/c/pmi238.html
   My authors  Follow this author

Marisa Miraldo

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Krystal Lau & Katharina Hauck & Marisa Miraldo, 2019. "Excess influenza hospital admissions and costs due to the 2009 H1N1 pandemic in England," Health Economics, John Wiley & Sons, Ltd., vol. 28(2), pages 175-188, February.

    Mentioned in:

    1. Ewan Gray’s journal round-up for 27th April 2020
      by Ewan Gray in The Academic Health Economists' Blog on 2020-04-27 11:00:00

Working papers

  1. Eliana Barrenho & Réka Halmai & Marisa Miraldo & Iván Tzintzun & Setti Raïs Ali & Léa Toulemon & Jean-Claude Dupont & Lise Rochaix, 2022. "Inequities in cancer drug development in terms of unmet medical need," Institut des Politiques Publiques halshs-03672739, HAL.

    Cited by:

    1. Gentilini, Arianna & Miraldo, Marisa, 2023. "The role of patient organisations in research and development: Evidence from rare diseases," Social Science & Medicine, Elsevier, vol. 338(C).

  2. Propper, Carol & Barrenho, Eliana & Gautier, Eric & Miraldo, Marisa & Rose, Christiern, 2020. "Innovation Diffusion and Physician Networks: Keyhole Surgery for Cancer in the English NHS," CEPR Discussion Papers 15515, C.E.P.R. Discussion Papers.

    Cited by:

    1. Marisa Miraldo & Carol Propper & Christiern Rose, 2020. "Identification of Peer Effects using Panel Data," Discussion Papers Series 639, School of Economics, University of Queensland, Australia.
    2. Meilin Möllenkamp & Benedetta Pongiglione & Stefan Rabbe & Aleksandra Torbica & Jonas Schreyögg, 2022. "Spillover effects and other determinants of medical device uptake in the presence of a medical guideline: An analysis of drug‐eluting stents in Germany and Italy," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 157-178, September.
    3. McKibbin, Rebecca, 2023. "The effect of RCTs on drug demand: Evidence from off-label cancer drugs," Journal of Health Economics, Elsevier, vol. 90(C).
    4. Avdic, Daniel & von Hinke, Stephanie & Lagerqvist, Bo & Propper, Carol & Vikström, Johan, 2024. "Do responses to news matter? Evidence from interventional cardiology," Journal of Health Economics, Elsevier, vol. 94(C).

  3. Barrenho, E.; & Miraldo, M.; & Propper, C; & Rose, C.;, 2019. "Peer and network effects in medical innovation: the case of laparoscopic surgery in the English NHS," Health, Econometrics and Data Group (HEDG) Working Papers 19/10, HEDG, c/o Department of Economics, University of York.

    Cited by:

    1. Áureo de Paula & Imran Rasul & Pedro CL Souza, 2023. "Identifying network ties from panel data: Theory and an application to tax competition," CeMMAP working papers 21/23, Institute for Fiscal Studies.

  4. Crea, Giovanni & Galizzi, Matteo M. & Linnosmaa, Ismo & Miraldo, Marisa, 2019. "Physician altruism and moral hazard: (no) evidence from Finnish national prescriptions data," LSE Research Online Documents on Economics 100301, London School of Economics and Political Science, LSE Library.

    Cited by:

    1. Brosig-Koch, Jeannette & Groß, Mona & Hennig-Schmidt, Heike & Kairies-Schwarz, Nadja & Wiesen, Daniel, 2021. "Physicians' incentives, patients' characteristics, and quality of care: A systematic experimental comparison of fee-for-service, capitation, and pay for performance," Ruhr Economic Papers 923, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.
    2. Hernandez-Pizarro, Helena & Nicodemo, Catia & Casasnovas, Guillem López, 2020. "Discontinuous System of Allowances: The Response of Prosocial Health-Care Professionals," IZA Discussion Papers 13758, Institute of Labor Economics (IZA).
    3. Goel, Rajeev K., 2020. "Are health care scams infectious? Empirical evidence on contagion in health care fraud," Open Access Publications from Kiel Institute for the World Economy 233680, Kiel Institute for the World Economy (IfW Kiel).
    4. Fiorentini, Gianluca & Bruni, Matteo Lippi & Mammi, Irene, 2022. "The same old medicine but cheaper: The impact of patent expiry on physicians’ prescribing behaviour," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 37-68.
    5. Olivia Bodnar & Hugh Gravelle & Nils Gutacker & Annika Herr, 2021. "Financial incentives and prescribing behaviour in primary care," Working Papers 181cherp, Centre for Health Economics, University of York.
    6. Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: Evidence from South African doctors," Journal of Development Economics, Elsevier, vol. 158(C).
    7. Lagarde, Mylène & Blaauw, Duane, 2022. "Overtreatment and benevolent provider moral hazard: evidence from South African doctors," LSE Research Online Documents on Economics 115383, London School of Economics and Political Science, LSE Library.
    8. Meng‐Chi Tang, 2023. "A structural analysis of physician agency and pharmaceutical demand," Health Economics, John Wiley & Sons, Ltd., vol. 32(7), pages 1453-1477, July.
    9. Rajeev K. Goel, 2020. "Medical professionals and health care fraud: Do they aid or check abuse?," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 41(4), pages 520-528, June.
    10. Attema, Arthur E. & Galizzi, Matteo M. & Groß, Mona & Hennig-Schmidt, Heike & Karay, Yassin & L’Haridon, Olivier & Wiesen, Daniel, 2023. "The formation of physician altruism," Journal of Health Economics, Elsevier, vol. 87(C).

  5. Galizzi, Matteo M. & Miraldo, Marisa & Stavropoulou, Charitini, 2016. "In sickness but not in wealth: field evidence on patients’ risk preferences in the financial and health domain," LSE Research Online Documents on Economics 64764, London School of Economics and Political Science, LSE Library.

    Cited by:

    1. Goldzahl, Léontine, 2017. "Contributions of risk preference, time orientation and perceptions to breast cancer screening regularity," Social Science & Medicine, Elsevier, vol. 185(C), pages 147-157.
    2. Pablo Brañas-Garza & Matteo M. Galizzi & Jeroen Nieboer, 2014. "Digit ratio and risk taking: Evidence from a large, multi-ethnic sample," Working Papers 14-23, Chapman University, Economic Science Institute.
    3. Izabela Jelovac & Philippe Polomé, 2017. "Incentives to patients versus incentives to health care providers: The users' perspective," Post-Print halshs-01524174, HAL.
    4. Martina Björkman Nyqvist & Lucia Corno & Damien de Walque & Jakob Svensson, 2022. "HIV, risk, and time preferences: Evidence from a general population sample in Lesotho," Health Economics, John Wiley & Sons, Ltd., vol. 31(5), pages 904-911, May.
    5. Galizzi, Matteo M. & Miraldo, Marisa & Stavropoulou, Charitini & van der Pol, Marjon, 2016. "Doctor–patient differences in risk and time preferences: a field experiment," LSE Research Online Documents on Economics 68143, London School of Economics and Political Science, LSE Library.
    6. Stefan A. Lipman & Arthur E. Attema, 2019. "Rabin's paradox for health outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1064-1071, August.
    7. Alejandro Arrieta & Ariadna García-Prado & Paula González & Jose Luis Pinto-Prades, 2016. "Risk Attitudes in Medical Decisions for Others: An Experimental Approach," Working Papers 16.07, Universidad Pablo de Olavide, Department of Economics.
    8. Galizzi, Matteo M. & Machado, Sara R. & Miniaci, Raffaele, 2016. "Temporal stability, cross-validity, and external validity of risk preferences measures: experimental evidence from a UK representative sample," LSE Research Online Documents on Economics 67554, London School of Economics and Political Science, LSE Library.
    9. Fredslund, Eskild Klausen & Mørkbak, Morten Raun & Gyrd-Hansen, Dorte, 2018. "Different domains – Different time preferences?," Social Science & Medicine, Elsevier, vol. 207(C), pages 97-105.
    10. Afschin Gandjour, 2022. "Financial Incentives in the Path to Recovery from the COVID-19 Pandemic," Applied Health Economics and Health Policy, Springer, vol. 20(1), pages 5-8, January.
    11. Attema, Arthur E. & L'Haridon, Olivier & van de Kuilen, Gijs, 2023. "Decomposing social risk preferences for health and wealth," Journal of Health Economics, Elsevier, vol. 90(C).
    12. Castro, M.F.; & Guccio, C.; & Romeo, D.;, 2022. "An assessment of physicians’ risk attitudes using laboratory and field data," Health, Econometrics and Data Group (HEDG) Working Papers 22/26, HEDG, c/o Department of Economics, University of York.
    13. Stolk-Vos, Aline C. & Attema, Arthur E. & Manzulli, Michele & van de Klundert, Joris J., 2022. "Do patients and other stakeholders value health service quality equally? A prospect theory based choice experiment in cataract care," Social Science & Medicine, Elsevier, vol. 294(C).
    14. Lépine, Aurélia & Treibich, Carole, 2020. "Risk aversion and HIV/AIDS: Evidence from Senegalese female sex workers," Social Science & Medicine, Elsevier, vol. 256(C).
    15. Biroli, Pietro & Bosworth, Steven J. & Della Giusta, Marina & Di Girolamo, Amalia & Jaworska, Sylvia & Vollen, Jeremy, 2020. "Framing the Predicted Impacts of COVID-19 Prophylactic Measures in Terms of Lives Saved Rather Than Deaths Is More Effective for Older People," IZA Discussion Papers 13753, Institute of Labor Economics (IZA).

  6. Galizzi, Matteo M. & Miraldo, Marisa & Stavropoulou, Charitini & van der Pol, Marjon, 2016. "Doctor–patient differences in risk and time preferences: a field experiment," LSE Research Online Documents on Economics 68143, London School of Economics and Political Science, LSE Library.

    Cited by:

    1. Stefan A. Lipman & Arthur E. Attema, 2019. "Rabin's paradox for health outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1064-1071, August.
    2. Alejandro Arrieta & Ariadna García-Prado & Paula González & Jose Luis Pinto-Prades, 2016. "Risk Attitudes in Medical Decisions for Others: An Experimental Approach," Working Papers 16.07, Universidad Pablo de Olavide, Department of Economics.
    3. Méndez, Susan J. & Scott, Anthony & Zhang, Yuting, 2021. "Gender differences in physician decisions to adopt new prescription drugs," Social Science & Medicine, Elsevier, vol. 277(C).
    4. Sebastian Neumann-Böhme & Stefan A. Lipman & Werner B. F. Brouwer & Arthur E. Attema, 2021. "Trust me; I know what I am doing investigating the effect of choice list elicitation and domain-relevant training on preference reversals in decision making for others," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 679-697, July.
    5. Yu Gao & Zhenxing Huang & Ning Liu & Jia Yang, 2024. "Are physicians rational under ambiguity?," Journal of Risk and Uncertainty, Springer, vol. 68(2), pages 183-203, April.
    6. Murong Yang & Laurence S. J. Roope & James Buchanan & Arthur E. Attema & Philip M. Clarke & A. Sarah Walker & Sarah Wordsworth, 2022. "Eliciting risk preferences that predict risky health behavior: A comparison of two approaches," Health Economics, John Wiley & Sons, Ltd., vol. 31(5), pages 836-858, May.
    7. Finocchiaro Castro, Massimo & Guccio, Calogero & Romeo, Domenica, 2022. "A systematic literature review of 10 years of behavioral research on health services," EconStor Preprints 266248, ZBW - Leibniz Information Centre for Economics.
    8. Irvine, Alastair & van der Pol, Marjon & Phimister, Euan, 2019. "A comparison of professional and private time preferences of General Practitioners," Social Science & Medicine, Elsevier, vol. 222(C), pages 256-264.
    9. Castro, M.F.; & Guccio, C.; & Romeo, D.;, 2022. "An assessment of physicians’ risk attitudes using laboratory and field data," Health, Econometrics and Data Group (HEDG) Working Papers 22/26, HEDG, c/o Department of Economics, University of York.
    10. Carlsson, Fredrik & Jacobsson, Gunnar & Lampi, Elina & Rönnestrand, Björn, 2021. "Peers, policy, and attitudes as drivers of antibiotic prescribing," Working Papers in Economics 803, University of Gothenburg, Department of Economics.
    11. van der Pol, Marjon & Scott, Anthony & Irvine, Alastair, 2019. "The migration of UK trained GPs to Australia: Does risk attitude matter?," Health Policy, Elsevier, vol. 123(11), pages 1093-1099.

  7. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "In sickness but not in wealth: Field evidence on patients’ risk preferences in the financial and health domain," Working Papers 31053, Imperial College, London, Imperial College Business School.

    Cited by:

    1. Pablo Brañas-Garza & Matteo M. Galizzi & Jeroen Nieboer, 2014. "Digit ratio and risk taking: Evidence from a large, multi-ethnic sample," Working Papers 14-23, Chapman University, Economic Science Institute.
    2. Izabela Jelovac & Philippe Polomé, 2017. "Incentives to patients versus incentives to health care providers: The users' perspective," Post-Print halshs-01524174, HAL.

  8. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.

    Cited by:

    1. Linde Colen & René Belderbos & Stijn Kelchtermans & Bart Leten, 2024. "Many are called, few are chosen: the role of science in drug development decisions," The Journal of Technology Transfer, Springer, vol. 49(2), pages 492-517, April.
    2. Michael Schlander & Karla Hernandez-Villafuerte & Chih-Yuan Cheng & Jorge Mestre-Ferrandiz & Michael Baumann, 2021. "How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment," PharmacoEconomics, Springer, vol. 39(11), pages 1243-1269, November.

  9. Miraldo, M & Galizzi, MM, 2012. "Are you what you eat? Experimental evidence on risk preferences and health habits," Working Papers 9792, Imperial College, London, Imperial College Business School.

    Cited by:

    1. Corazzini, Luca & Filippin, Antonio & Vanin, Paolo, 2014. "Economic Behavior under Alcohol Influence: An Experiment on Time, Risk, and Social Preferences," IZA Discussion Papers 8170, Institute of Labor Economics (IZA).
    2. Matteo M. Galizzi, 2014. "What Is Really Behavioral in Behavioral Health Policy? And Does It Work?," Applied Economic Perspectives and Policy, Agricultural and Applied Economics Association, vol. 36(1), pages 25-60.
    3. Galizzi, Matteo M. & Miraldo, Marisa & Stavropoulou, Charitini & van der Pol, Marjon, 2016. "Doctor–patient differences in risk and time preferences: a field experiment," LSE Research Online Documents on Economics 68143, London School of Economics and Political Science, LSE Library.
    4. Vasilios Kosteas, 2015. "Physical activity and time preference," International Journal of Health Economics and Management, Springer, vol. 15(4), pages 361-386, December.
    5. Galizzi, Matteo M. & Machado, Sara R. & Miniaci, Raffaele, 2016. "Temporal stability, cross-validity, and external validity of risk preferences measures: experimental evidence from a UK representative sample," LSE Research Online Documents on Economics 67554, London School of Economics and Political Science, LSE Library.
    6. Klajdi Bregu & Cary Deck & Lindsay Ham & Salar Jahedi, 2016. "The Effects of Alcohol Use on Economic Decision Making," Working Papers 16-03, Chapman University, Economic Science Institute.
    7. Kaywana Raeburn & Jim Engle-Warnick & Sonia Laszlo, 2016. "Determinants of Food Consumption Choices: Experimental Evidence from St. Kitts," CIRANO Working Papers 2016s-43, CIRANO.
    8. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "Doctor-patient differences in risk preferences, and their links to decision-making: a field experiment," Working Papers 12578, Imperial College, London, Imperial College Business School.
    9. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "In sickness but not in wealth: Field evidence on patients’ risk preferences in the financial and health domain," Working Papers 31053, Imperial College, London, Imperial College Business School.
    10. Luca Corazzini & Antonio Filippin & Paolo Vanin, 2015. "Economic Behavior under the Influence of Alcohol: An Experiment on Time Preferences, Risk-Taking, and Altruism," PLOS ONE, Public Library of Science, vol. 10(4), pages 1-25, April.

  10. Matteo M. Galizzi & Marisa Miraldo, 2010. "Are You What You Eat? Experimental Evidence on Health Habits and Risk Preferences," Working Papers 1003, University of Brescia, Department of Economics.

    Cited by:

    1. Corazzini, Luca & Filippin, Antonio & Vanin, Paolo, 2014. "Economic Behavior under Alcohol Influence: An Experiment on Time, Risk, and Social Preferences," IZA Discussion Papers 8170, Institute of Labor Economics (IZA).
    2. Vasilios Kosteas, 2015. "Physical activity and time preference," International Journal of Health Economics and Management, Springer, vol. 15(4), pages 361-386, December.
    3. Galizzi, Matteo M. & Machado, Sara R. & Miniaci, Raffaele, 2016. "Temporal stability, cross-validity, and external validity of risk preferences measures: experimental evidence from a UK representative sample," LSE Research Online Documents on Economics 67554, London School of Economics and Political Science, LSE Library.
    4. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "Doctor-patient differences in risk preferences, and their links to decision-making: a field experiment," Working Papers 12578, Imperial College, London, Imperial College Business School.
    5. Brañas-Garza, Pablo & Espín, Antonio M. & Lenkei, Balint, 2015. "BMI is not related to altruism, fairness, trust or reciprocity: Experimental evidence from the field and the lab," MPRA Paper 68184, University Library of Munich, Germany.
    6. Miraldo, M & Galizzi, M & Stavropoulou, C, 2013. "In sickness but not in wealth: Field evidence on patients’ risk preferences in the financial and health domain," Working Papers 31053, Imperial College, London, Imperial College Business School.

  11. Miraldo, M, 2009. "Economies of scale and scope in the English hospital sector," Working Papers 4202, Imperial College, London, Imperial College Business School.

    Cited by:

    1. Michael Freeman & Nicos Savva & Stefan Scholtes, 2021. "Economies of Scale and Scope in Hospitals: An Empirical Study of Volume Spillovers," Management Science, INFORMS, vol. 67(2), pages 673-697, February.

  12. Marisa Miraldo & Luigi Siciliani & Andrew Street, 2008. "Price Adjustment in the Hospital Sector," Working Papers 041cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Galina Besstremyannaya, 2014. "The adverse effects of value-based purchasing in health care: dynamic quantile regression with endogeneity," Discussion Papers 14-006, Stanford Institute for Economic Policy Research.
    2. Ching-to Albert Ma & Henry Y. Mak, 2013. "Information Disclosure and the Equivalence of Prospective Payment and Cost Reimbursement," Boston University - Department of Economics - Working Papers Series 2013-018, Boston University - Department of Economics.
    3. Galina Besstremyannaya & Sergei Golovan, 2019. "Physician’s altruism in incentive contracts: Medicare’s quality race," CINCH Working Paper Series 1903, Universitaet Duisburg-Essen, Competent in Competition and Health.
    4. Siciliani, Luigi & Kifmann, Mathias, 2014. "Average-cost Pricing and Dynamic Selection Incentives in the Hospital Sector," CEPR Discussion Papers 10155, C.E.P.R. Discussion Papers.
    5. Marisa Miraldo & Luigi Siciliani & Andrew Street, 2008. "Price Adjustment in the Hospital Sector," Working Papers 041cherp, Centre for Health Economics, University of York.
    6. Michele Bisceglia & Roberto Cellini & Luca Grilli, 2018. "Regional regulators in health care service under quality competition: A game theoretical model," Health Economics, John Wiley & Sons, Ltd., vol. 27(11), pages 1821-1842, November.
    7. Jurgita Januleviciute & Jan Erik Askildsen & Oddvar Kaarboe & Luigi Siciliani & Matt Sutton, 2016. "How do Hospitals Respond to Price Changes? Evidence from Norway," Health Economics, John Wiley & Sons, Ltd., vol. 25(5), pages 620-636, May.
    8. Houyuan Jiang & Zhan Pang & Sergei Savin, 2012. "Performance-Based Contracts for Outpatient Medical Services," Manufacturing & Service Operations Management, INFORMS, vol. 14(4), pages 654-669, October.
    9. Michele Bisceglia & Roberto Cellini & Luigi Siciliani & Odd Rune Straume, 2019. "Optimal dynamic volume-based price regulation," NIPE Working Papers 06/2019, NIPE - Universidade do Minho.
    10. Houyuan Jiang & Zhan Pang & Sergei Savin, 2020. "Performance Incentives and Competition in Health Care Markets," Production and Operations Management, Production and Operations Management Society, vol. 29(5), pages 1145-1164, May.
    11. Galina Besstremyannaya, 2015. "Heterogeneous effect of residency matching and prospective payment on labor returns and hospital scale economies," Discussion Papers 15-001, Stanford Institute for Economic Policy Research.
    12. Xidong Guo, 2024. "An analysis of a rural hospital's investment decision under different payment systems," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 714-747, April.
    13. Li‐Lin Liang, 2015. "Do Diagnosis‐Related Group‐Based Payments Incentivise Hospitals to Adjust Output Mix?," Health Economics, John Wiley & Sons, Ltd., vol. 24(4), pages 454-469, April.
    14. Houyuan Jiang & Zhan Pang & Sergei Savin, 2017. "Improving Patient Access to Care: Performance Incentives and Competition in Healthcare Markets," Working Papers 2017/01, Cambridge Judge Business School, University of Cambridge.
    15. Galina Besstremyannaya, 2015. "The adverse effects of incentives regulation in health care: a comparative analysis with the U.S. and Japanese hospital data," Working Papers w0218, Center for Economic and Financial Research (CEFIR).
    16. Galina Besstremyannaya, 2015. "The adverse effects of incentives regulation in health care: a comparative analysis with the U.S. and Japanese hospital data," Working Papers w0218, New Economic School (NES).

  13. Anne Mason & Marisa Miraldo & Luigi Siciliani & Peter Sivey & Andrew Street, 2008. "Establishing a Fair Playing Field for Payment by Results," Working Papers 039cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Zack Cooper & Stephen Gibbons & Matthew Skellern, 2016. "Does competition from private surgical centres improve public hospitals' performance? Evidence from the English National Health Service," CEP Discussion Papers dp1434, Centre for Economic Performance, LSE.
    2. Street, Andrew & Sivey, Peter & Mason, Anne & Miraldo, Marisa & Siciliani, Luigi, 2010. "Are English treatment centres treating less complex patients?," Health Policy, Elsevier, vol. 94(2), pages 150-157, February.
    3. Petrou, Panagiotis & Vandoros, Sotiris, 2018. "Healthcare reforms in Cyprus 2013–2017: Does the crisis mark the end of the healthcare sector as we know it?," Health Policy, Elsevier, vol. 122(2), pages 75-80.
    4. Moscelli, Giuseppe & Gravelle, Hugh & Siciliani, Luigi & Gutacker, Nils, 2018. "The effect of hospital ownership on quality of care: Evidence from England," Journal of Economic Behavior & Organization, Elsevier, vol. 153(C), pages 322-344.
    5. Klein-Hitpaß, Uwe & Scheller-Kreinsen, David, 2015. "Policy trends and reforms in the German DRG-based hospital payment system," Health Policy, Elsevier, vol. 119(3), pages 252-257.
    6. Galizzi, Matteo M. & Miraldo, Marisa, 2011. "The effects of hospitals' governance on optimal contracts: Bargaining vs. contracting," Journal of Health Economics, Elsevier, vol. 30(2), pages 408-424, March.

  14. Roberta Longo & Marisa Miraldo & Andrew Street, 2008. "Price regulation of pluralistic markets subject to provider collusion," Working Papers 045cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Martin Janíčko & Ivo Koubek, 2012. "Informační asymetrie a systém dvojího standardu ve vztahu zdravotník - pacient [Information Assymetry and Double Standard in the Doctor-Patient Relationship]," Politická ekonomie, Prague University of Economics and Business, vol. 2012(3), pages 362-379.
    2. Jana Chvalkovská & Petr Janský & Jiří Skuhrovec, 2012. "Listinné akcie na majitele a veřejné zakázky [Bearer Shares in Paper Form and Public Procurement]," Politická ekonomie, Prague University of Economics and Business, vol. 2012(3), pages 349-361.

  15. Marisa Miraldo, 2007. "Reference Pricing Versus Co-Payment in the Pharmaceutical Industry: Price, Quality and Market Coverage," Working Papers 025cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy," NBER Working Papers 14567, National Bureau of Economic Research, Inc.
    2. Miraldo, Marisa, 2009. "Reference pricing and firms' pricing strategies," Journal of Health Economics, Elsevier, vol. 28(1), pages 176-197, January.

  16. Marisa Miraldo, 2007. "Hospital Financing and the Development and Adoption of New Technologies," Working Papers 026cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Pedro Pita Barros & Xavier Martínez-Giralt, 2009. "Technological adoption in health care," Working Papers 413, Barcelona School of Economics.
    2. Seungchul Lee & Robert Rosenman, 2012. "Reimbursement and Investment: Propsective Payment and For-Profit Hospitals' Market Share," Working Papers 2012-3, School of Economic Sciences, Washington State University.
    3. Barros Pedro Pita & Martinez-Giralt Xavier, 2015. "Technological Adoption in Health Care – The Role of Payment Systems," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 15(2), pages 709-745, April.
    4. Finocchiaro Castro, Massimo & Guccio, Calogero & Pignataro, Giacomo & Rizzo, Ilde, 2014. "The effects of reimbursement mechanisms on medical technology diffusion in the hospital sector in the Italian NHS," Health Policy, Elsevier, vol. 115(2), pages 215-229.

  17. Marisa Miraldo, 2007. "Reference Pricing Versus Co-Payment in the Pharmaceutical Industry: Firm's Pricing Strategies," Working Papers 027cherp, Centre for Health Economics, University of York.

    Cited by:

    1. David Bardey & Bruno Jullien & Jean-Marie Lozachmeur, 2013. "Health Insurance and Diversity of Treatment: A Policy Mix Perspective," CESifo Working Paper Series 4111, CESifo.
    2. Birg, Laura, 2013. "Pharmaceutical regulation and health policy objectives," University of Göttingen Working Papers in Economics 183, University of Goettingen, Department of Economics.

  18. Marisa Miraldo & Maria Goddard & Peter C Smith, 2006. "The incentive effects of payment by results," Working Papers 019cherp, Centre for Health Economics, University of York.

    Cited by:

    1. David Epstein & Anne Mason, 2006. "Costs and prices for inpatient care in England: Mirror twins or distant cousins?," Health Care Management Science, Springer, vol. 9(3), pages 233-242, August.
    2. Andrew Street & Kirsi Vitikainen & Afsaneh Bjorvatn & Anne Hvenegaard, 2007. "Introducing activity-based financing: a review of experience in Australia, Denmark, Norway and Sweden," Working Papers 030cherp, Centre for Health Economics, University of York.
    3. Galina Besstremyannaya, 2014. "Heterogeneous effect of coinsurance rate on healthcare costs: generalized finite mixtures and matching estimators," Discussion Papers 14-014, Stanford Institute for Economic Policy Research.
    4. Stephen Martin & Andrew Street & Lu Han & John Hutton, 2014. "The impact of hospital financing on the quality of inpatient care in England," Working Papers 105cherp, Centre for Health Economics, University of York.
    5. Anne Mason & Maria Goddard, 2009. "Payment by results in mental health: A review of the international literature and an economic assessment of the approach in the English NHS," Working Papers 050cherp, Centre for Health Economics, University of York.
    6. Or., Zeynep, 2014. "Implementation of DRG Payment in France: Issues and recent developments," Health Policy, Elsevier, vol. 117(2), pages 146-150.
    7. David Scheller‐Kreinsen & on behalf of the EuroDRG group, 2012. "How Well Do Diagnosis‐Related Group Systems Group Breast Cancer Surgery Patients?—Evidence From 10 European Countries," Health Economics, John Wiley & Sons, Ltd., vol. 21(S2), pages 41-54, August.

Articles

  1. Jinyang Chen & Marisa Miraldo, 2022. "The impact of hospital price and quality transparency tools on healthcare spending: a systematic review," Health Economics Review, Springer, vol. 12(1), pages 1-12, December.

    Cited by:

    1. Christopher T. Robertson & Wendy Netter Epstein & Hansoo Ko, 2023. "The effects of price transparency and debt collection policies on intentions to consume recommended health care: A randomized vignette experiment," Journal of Empirical Legal Studies, John Wiley & Sons, vol. 20(4), pages 941-960, December.

  2. Rizmie, Dheeya & de Preux, Laure & Miraldo, Marisa & Atun, Rifat, 2022. "Impact of extreme temperatures on emergency hospital admissions by age and socio-economic deprivation in England," Social Science & Medicine, Elsevier, vol. 308(C).

    Cited by:

    1. Gibney, Garreth & McDermott, Thomas K.J. & Cullinan, John, 2023. "Temperature, morbidity, and behavior in milder climates," Economic Modelling, Elsevier, vol. 118(C).
    2. Filomena, Mattia & Picchio, Matteo, 2023. "Unsafe temperatures, unsafe jobs: The impact of weather conditions on work-related injuries," GLO Discussion Paper Series 1280, Global Labor Organization (GLO).
    3. Duffy, Kelly & De Bruin, Kelly & Henry, Loïc & Kweku-Kyei, Clement & Nolan, Anne & Walsh, Brendan, 2024. "Health impacts of climate change and mitigation policies in Ireland," Research Series, Economic and Social Research Institute (ESRI), number RS188.
    4. Fangjin Xu & Qingxu Huang & Huanbi Yue & Xingyun Feng & Haoran Xu & Chunyang He & Peng Yin & Brett A. Bryan, 2023. "The challenge of population aging for mitigating deaths from PM2.5 air pollution in China," Nature Communications, Nature, vol. 14(1), pages 1-13, December.

  3. Barrenho, Eliana & Halmai, Réka & Miraldo, Marisa & Tzintzun, Iván & Raïs Ali, Setti & Toulemon, Léa & Dupont, Jean-Claude K. & Rochaix, Lise, 2022. "Inequities in cancer drug development in terms of unmet medical need," Social Science & Medicine, Elsevier, vol. 302(C).
    See citations under working paper version above.
  4. Surya Singh & Mujaheed Shaikh & Katharina Hauck & Marisa Miraldo, 2021. "Impacts of introducing and lifting nonpharmaceutical interventions on COVID-19 daily growth rate and compliance in the United States," Proceedings of the National Academy of Sciences, Proceedings of the National Academy of Sciences, vol. 118(12), pages 2021359118-, March.

    Cited by:

    1. Mellace, Giovanni & Crudu, Frederico & Di Stefano, Roberta & Tiezzi, Silvia, 2022. "The Gray Zone," Discussion Papers on Economics 5/2022, University of Southern Denmark, Department of Economics.
    2. Mello, Marco & Moscelli, Giuseppe, 2021. "Voting, Contagion and the Trade-Off between Public Health and Political Rights: Quasi-Experimental Evidence from the Italian 2020 Polls," IZA Discussion Papers 14658, Institute of Labor Economics (IZA).
    3. Virat Agrawal & Jonathan H. Cantor & Neeraj Sood & Christopher M. Whaley, 2021. "The Impact of the COVID-19 Pandemic and Policy Responses on Excess Mortality," NBER Working Papers 28930, National Bureau of Economic Research, Inc.
    4. Lixin Lin & Yanji Zhao & Boqiang Chen & Daihai He, 2022. "Multiple COVID-19 Waves and Vaccination Effectiveness in the United States," IJERPH, MDPI, vol. 19(4), pages 1-12, February.
    5. Theologos Dergiades & Costas Milas & Elias Mossialos & Theodore Panagiotidis, 2023. "COVID-19 anti-contagion policies and economic support measures in the USA," Oxford Economic Papers, Oxford University Press, vol. 75(3), pages 613-630.
    6. Lili Li & Araz Taeihagh & Si Ying Tan, 2023. "A scoping review of the impacts of COVID-19 physical distancing measures on vulnerable population groups," Nature Communications, Nature, vol. 14(1), pages 1-19, December.
    7. Galanis, Giorgos & Georgiadis, Andreas, 2024. "Socioeconomic conditions and contagion dynamics of the COVID-19 pandemic with and without mitigation measures: Evidence from 185 countries," World Development, Elsevier, vol. 175(C).
    8. Yong Ge & Xilin Wu & Wenbin Zhang & Xiaoli Wang & Die Zhang & Jianghao Wang & Haiyan Liu & Zhoupeng Ren & Nick W. Ruktanonchai & Corrine W. Ruktanonchai & Eimear Cleary & Yongcheng Yao & Amy Wesolowsk, 2023. "Effects of public-health measures for zeroing out different SARS-CoV-2 variants," Nature Communications, Nature, vol. 14(1), pages 1-12, December.
    9. Lu Zhong & Mamadou Diagne & Qi Wang & Jianxi Gao, 2022. "Vaccination and three non-pharmaceutical interventions determine the dynamics of COVID-19 in the US," Palgrave Communications, Palgrave Macmillan, vol. 9(1), pages 1-12, December.
    10. William Clyde & Andreas Kakolyris & Georgios Koimisis, 2021. "A Study of the Effectiveness of Governmental Strategies for Managing Mortality from COVID-19," Eastern Economic Journal, Palgrave Macmillan;Eastern Economic Association, vol. 47(4), pages 487-505, October.

  5. Barrenho, Eliana & Miraldo, Marisa & Propper, Carol & Walsh, Brendan, 2021. "The importance of surgeons and their peers in adoption and diffusion of innovation: An observational study of laparoscopic colectomy adoption and diffusion in England," Social Science & Medicine, Elsevier, vol. 272(C).

    Cited by:

    1. Méndez, Susan J. & Scott, Anthony & Zhang, Yuting, 2021. "Gender differences in physician decisions to adopt new prescription drugs," Social Science & Medicine, Elsevier, vol. 277(C).
    2. Maynou, Laia & McGuire, Alistair & Serra-Sastre, Victoria, 2024. "What happens when the tasks dry up? Exploring the impact of medical technology on workforce planning," LSE Research Online Documents on Economics 124065, London School of Economics and Political Science, LSE Library.
    3. Godager , Geir & Scott, Anthony, 2023. "Physician Behavior and Health Outcomes," HERO Online Working Paper Series 2023:3, University of Oslo, Health Economics Research Programme.
    4. Meilin Möllenkamp & Benedetta Pongiglione & Stefan Rabbe & Aleksandra Torbica & Jonas Schreyögg, 2022. "Spillover effects and other determinants of medical device uptake in the presence of a medical guideline: An analysis of drug‐eluting stents in Germany and Italy," Health Economics, John Wiley & Sons, Ltd., vol. 31(S1), pages 157-178, September.

  6. Francisco Goiana-da-Silva & Milton Severo & David Cruz e Silva & Maria João Gregório & Luke N Allen & Magdalena Muc & Alexandre Morais Nunes & Duarte Torres & Marisa Miraldo & Hutan Ashrafian & Ana Ri, 2020. "Projected impact of the Portuguese sugar-sweetened beverage tax on obesity incidence across different age groups: A modelling study," PLOS Medicine, Public Library of Science, vol. 17(3), pages 1-17, March.

    Cited by:

    1. Goncalves, Judite & Merenda, Roxanne & dos Santos, João Pereira, 2022. "Not so sweet: The impact of the Portuguese soda tax on producers," Ruhr Economic Papers 938, RWI - Leibniz-Institut für Wirtschaftsforschung, Ruhr-University Bochum, TU Dortmund University, University of Duisburg-Essen.

  7. Eliana Barrenho & Marisa Miraldo & Peter C. Smith, 2019. "Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 123-143, January.

    Cited by:

    1. Javad Moradpour & Aidan Hollis, 2020. "Patient income and health innovation," Health Economics, John Wiley & Sons, Ltd., vol. 29(12), pages 1795-1803, December.
    2. Massimo FLORIO, 2020. "Biomed Europa: after the coronavirus, a public infrastructure to overcome the pharmaceutical oligopoly," CIRIEC Working Papers 2008, CIRIEC - Université de Liège.
    3. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    4. Barrenho, Eliana & Halmai, Réka & Miraldo, Marisa & Tzintzun, Iván & Raïs Ali, Setti & Toulemon, Léa & Dupont, Jean-Claude K. & Rochaix, Lise, 2022. "Inequities in cancer drug development in terms of unmet medical need," Social Science & Medicine, Elsevier, vol. 302(C).
    5. Gentilini, Arianna & Miraldo, Marisa, 2023. "The role of patient organisations in research and development: Evidence from rare diseases," Social Science & Medicine, Elsevier, vol. 338(C).
    6. Vijay Mohan & Munirul Nabin, 2023. "A note on disease burden and pharmaceutical R&D," Australian Economic Papers, Wiley Blackwell, vol. 62(4), pages 633-649, December.
    7. Rabbani, Maysam, 2021. "Mergers with Future Rivals Can Boost Prices, Intensify Market Concentration, and Bar Entry," MPRA Paper 112864, University Library of Munich, Germany, revised 26 Apr 2022.
    8. Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.

  8. Krystal Lau & Katharina Hauck & Marisa Miraldo, 2019. "Excess influenza hospital admissions and costs due to the 2009 H1N1 pandemic in England," Health Economics, John Wiley & Sons, Ltd., vol. 28(2), pages 175-188, February.

    Cited by:

    1. Matthias Klumpp & Dominic Loske & Silvio Bicciato, 2022. "COVID-19 health policy evaluation: integrating health and economic perspectives with a data envelopment analysis approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(8), pages 1263-1285, November.
    2. Fraser Summerfield & Livio Di Matteo, 2021. "Influenza Pandemics and Macroeconomic Fluctuations in Recent Economic History," Working Papers 210002, Canadian Centre for Health Economics.
    3. Ian M. Trotter & Lu'is A. C. Schmidt & Bruno C. M. Pinto & Andrezza L. Batista & J'essica Pellenz & Maritza Isidro & Aline Rodrigues & Attawan G. S. Suela & Loredany Rodrigues, 2020. "COVID-19 and Global Economic Growth: Policy Simulations with a Pandemic-Enabled Neoclassical Growth Model," Papers 2005.13722, arXiv.org, revised Jun 2020.
    4. Doran, Áine & Colvin, Christopher L. & McLaughlin, Eoin, 2023. "What can we learn from historical pandemics? A systematic review of the literature," QUCEH Working Paper Series 23-10, Queen's University Belfast, Queen's University Centre for Economic History.
    5. Peter Sivey & Richard McAllister & Hassan Vally & Anna Burgess & Anne-Maree Kelly, 2019. "Anatomy of a demand shock: Quantitative analysis of crowding in hospital emergency departments in Victoria, Australia during the 2009 influenza pandemic," PLOS ONE, Public Library of Science, vol. 14(9), pages 1-11, September.
    6. Emilio Gutierrez & Adrian Rubli, 2021. "Shocks to Hospital Occupancy and Mortality: Evidence from the 2009 H1N1 Pandemic," Management Science, INFORMS, vol. 67(9), pages 5943-5952, September.
    7. E.V. Popov, 2021. "Drivers of the Economy in the Context of the Coronavirus Pandemic," Journal of Applied Economic Research, Graduate School of Economics and Management, Ural Federal University, vol. 20(1), pages 5-30.

  9. Crea, Giovanni & Galizzi, Matteo M. & Linnosmaa, Ismo & Miraldo, Marisa, 2019. "Physician altruism and moral hazard: (no) Evidence from Finnish national prescriptions data," Journal of Health Economics, Elsevier, vol. 65(C), pages 153-169.
    See citations under working paper version above.
  10. Miraldo, Marisa & Propper, Carol & Williams, Rachael I., 2018. "The impact of publicly subsidised health insurance on access, behavioural risk factors and disease management," Social Science & Medicine, Elsevier, vol. 217(C), pages 135-151.

    Cited by:

    1. Agung Dwi Laksono & Rukmini Rukmini & Ratna Dwi Wulandari, 2020. "Regional disparities in antenatal care utilization in Indonesia," PLOS ONE, Public Library of Science, vol. 15(2), pages 1-13, February.
    2. Dimitrovová, Klára & Perelman, Julian & Serrano-Alarcón, Manuel, 2020. "Effect of a national primary care reform on avoidable hospital admissions (2000–2015): A difference-in-difference analysis," Social Science & Medicine, Elsevier, vol. 252(C).

  11. Galizzi Matteo M. & Miraldo Marisa, 2017. "Are You What You Eat? Healthy Behaviour and Risk Preferences," The B.E. Journal of Economic Analysis & Policy, De Gruyter, vol. 17(1), pages 1-25, January.

    Cited by:

    1. Lohmann, Paul M. & Gsottbauer, Elisabeth & You, Jing & Kontoleon, Andreas, 2023. "Anti-social behaviour and economic decision-making: panel experimental evidence in the wake of COVID-19," LSE Research Online Documents on Economics 117702, London School of Economics and Political Science, LSE Library.
    2. Thomas, Ranjeeta & Galizzi, Matteo M. & Moorhouse, Louisa & Nyamukapa, Constance & Hallett, Timothy B., 2024. "Do risk, time and prosocial preferences predict risky sexual behaviour of youths in a low-income, high-risk setting?," LSE Research Online Documents on Economics 121013, London School of Economics and Political Science, LSE Library.
    3. Chiara Pastore & Stefanie Schurer & Agnieszka Tymula & Nicholas Fuller & Ian Caterson, 2023. "Economic preferences and obesity: Evidence from a clinical lab‐in‐field study," Health Economics, John Wiley & Sons, Ltd., vol. 32(9), pages 2147-2167, September.
    4. Yating Chuang & John Chung-En Liu, 2020. "Who wears a mask? Gender differences in risk behaviors in the COVID-19 early days in Taiwan," Economics Bulletin, AccessEcon, vol. 40(4), pages 2619-2627.
    5. Archana Dang, 2023. "Time preferences and obesity: Evidence from urban India," Agricultural Economics, International Association of Agricultural Economists, vol. 54(4), pages 487-514, July.
    6. Pastore, Chiara & Schurer, Stefanie & Tymula, Agnieszka & Fuller, Nicholas & Caterson, Ian, 2020. "Economic Preferences and Obesity: Evidence from a Clinical Lab-in-Field Experiment," IZA Discussion Papers 13915, Institute of Labor Economics (IZA).
    7. Kalwij, Adriaan, 2023. "Risk preferences, preventive behaviour, and the probability of a loss: Empirical evidence from the COVID-19 pandemic," Social Science & Medicine, Elsevier, vol. 334(C).

  12. Galizzi, Matteo M. & Miraldo, Marisa & Stavropoulou, Charitini & van der Pol, Marjon, 2016. "Doctor–patient differences in risk and time preferences: A field experiment," Journal of Health Economics, Elsevier, vol. 50(C), pages 171-182.
    See citations under working paper version above.
  13. Matteo M. Galizzi & Marisa Miraldo & Charitini Stavropoulou, 2016. "In Sickness but Not in Wealth," Medical Decision Making, , vol. 36(4), pages 503-517, May.

    Cited by:

    1. Izabela Jelovac & Philippe Polomé, 2017. "Incentives to patients versus incentives to health care providers: The users' perspective," Post-Print halshs-01524174, HAL.
    2. Martina Björkman Nyqvist & Lucia Corno & Damien de Walque & Jakob Svensson, 2022. "HIV, risk, and time preferences: Evidence from a general population sample in Lesotho," Health Economics, John Wiley & Sons, Ltd., vol. 31(5), pages 904-911, May.
    3. Galizzi, Matteo M. & Miraldo, Marisa & Stavropoulou, Charitini & van der Pol, Marjon, 2016. "Doctor–patient differences in risk and time preferences: a field experiment," LSE Research Online Documents on Economics 68143, London School of Economics and Political Science, LSE Library.
    4. Stefan A. Lipman & Arthur E. Attema, 2019. "Rabin's paradox for health outcomes," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1064-1071, August.
    5. Alejandro Arrieta & Ariadna García-Prado & Paula González & Jose Luis Pinto-Prades, 2016. "Risk Attitudes in Medical Decisions for Others: An Experimental Approach," Working Papers 16.07, Universidad Pablo de Olavide, Department of Economics.
    6. Fredslund, Eskild Klausen & Mørkbak, Morten Raun & Gyrd-Hansen, Dorte, 2018. "Different domains – Different time preferences?," Social Science & Medicine, Elsevier, vol. 207(C), pages 97-105.
    7. Attema, Arthur E. & L'Haridon, Olivier & van de Kuilen, Gijs, 2023. "Decomposing social risk preferences for health and wealth," Journal of Health Economics, Elsevier, vol. 90(C).
    8. Stolk-Vos, Aline C. & Attema, Arthur E. & Manzulli, Michele & van de Klundert, Joris J., 2022. "Do patients and other stakeholders value health service quality equally? A prospect theory based choice experiment in cataract care," Social Science & Medicine, Elsevier, vol. 294(C).
    9. Lépine, Aurélia & Treibich, Carole, 2020. "Risk aversion and HIV/AIDS: Evidence from Senegalese female sex workers," Social Science & Medicine, Elsevier, vol. 256(C).
    10. Biroli, Pietro & Bosworth, Steven J. & Della Giusta, Marina & Di Girolamo, Amalia & Jaworska, Sylvia & Vollen, Jeremy, 2020. "Framing the Predicted Impacts of COVID-19 Prophylactic Measures in Terms of Lives Saved Rather Than Deaths Is More Effective for Older People," IZA Discussion Papers 13753, Institute of Labor Economics (IZA).

  14. Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.

    Cited by:

    1. Patrícia Véras Marrone & Fabio Rampazzo Mathias & Wanderley Marques Bernardo & Marina Feliciano Orlandini & Maria Carolina Andrade Serafim & Maria Lídia Rebello Pinho Dias Scoton & Juliano Marçal Lope, 2023. "Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review," Economies, MDPI, vol. 11(1), pages 1-21, January.
    2. Beth Woods & Aimée Fox & Mark Sculpher & Karl Claxton, 2021. "Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems," Health Economics, John Wiley & Sons, Ltd., vol. 30(11), pages 2649-2666, November.

  15. Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Erratum to: Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 447-447, May.

    Cited by:

    1. Patrícia Véras Marrone & Fabio Rampazzo Mathias & Wanderley Marques Bernardo & Marina Feliciano Orlandini & Maria Carolina Andrade Serafim & Maria Lídia Rebello Pinho Dias Scoton & Juliano Marçal Lope, 2023. "Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review," Economies, MDPI, vol. 11(1), pages 1-21, January.
    2. Beth Woods & Aimée Fox & Mark Sculpher & Karl Claxton, 2021. "Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems," Health Economics, John Wiley & Sons, Ltd., vol. 30(11), pages 2649-2666, November.

  16. Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2013. "The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies," PharmacoEconomics, Springer, vol. 31(5), pages 445-454, May.

    Cited by:

    1. Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
    2. Alan Haycox, 2013. "How Much Should the NHS Pay for a QALY?," PharmacoEconomics, Springer, vol. 31(5), pages 357-359, May.

  17. Matteo Galizzi & Simone Ghislandi & Marisa Miraldo, 2011. "Effects of Reference Pricing in Pharmaceutical Markets," PharmacoEconomics, Springer, vol. 29(1), pages 17-33, January.

    Cited by:

    1. Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2015. "Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform," Discussion Paper Series in Economics 11/2015, Norwegian School of Economics, Department of Economics.
    2. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
    3. Izabela Jelovac, 2015. "On the relationship between the negotiated prices of pharmaceuticals and the patients' co-payment," Economics Bulletin, AccessEcon, vol. 35(1), pages 481-493.
    4. Nika Marđetko & Mitja Kos, 2018. "Introduction of therapeutic reference pricing in Slovenia and its economic consequences," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 571-584, May.
    5. Timothy T. Brown & James C. Robinson, 2016. "Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending," Health Economics, John Wiley & Sons, Ltd., vol. 25(6), pages 740-749, June.
    6. Patrizio Armeni & Claudio Jommi & Monica Otto, 2016. "The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(8), pages 963-977, November.
    7. Simone Ghislandi & Patrizio Armeni & Claudio Jommi, 2013. "The impact of generic reference pricing in Italy, a decade on," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 959-969, December.
    8. Michael Berger & Markus Pock & Miriam Reiss & Gerald Röhrling & Thomas Czypionka, 2023. "Exploring the effectiveness of demand-side retail pharmaceutical expenditure reforms," International Journal of Health Economics and Management, Springer, vol. 23(1), pages 149-172, March.
    9. Toon van der Gronde & Carin A Uyl-de Groot & Toine Pieters, 2017. "Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-34, August.
    10. Charitini Stavropoulou & Tommaso Valletti, 2015. "Compulsory licensing and access to drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 83-94, January.
    11. R. Rovbel L. & Р. Ровбель Л., 2018. "Анализ проблем и возможностей использования референтного ценообразования органами государственной власти и местного самоуправления в сфере закупок и жилищного строительства // Analyzing the Problems a," Управленческие науки // Management Science, ФГОБУВО Финансовый университет при Правительстве Российской Федерации // Financial University under The Government of Russian Federation, vol. 8(2), pages 44-51.
    12. Straume, Odd Rune, 2023. "Therapeutic reference pricing and drug innovation incentives," Economics Letters, Elsevier, vol. 222(C).
    13. A. Carletto & A. Cicchetti & S. Coretti & V. Moramarco & M. Ruggeri, 2019. "Money back guarantee? A cost–benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals," Eurasian Business Review, Springer;Eurasia Business and Economics Society, vol. 9(1), pages 89-101, March.
    14. F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas, 2017. "Endogenous versus exogenous generic reference pricing for pharmaceuticals," International Journal of Health Economics and Management, Springer, vol. 17(4), pages 413-432, December.
    15. Eduardo Costa & Carolina Santos, 2022. "Pharmaceutical pricing dynamics in an internal reference pricing system: evidence from changing drugs’ reimbursements," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(9), pages 1497-1518, December.
    16. Sabine Vogler & Guillaume Dedet & Hanne Bak Pedersen, 2019. "Financial Burden of Prescribed Medicines Included in Outpatient Benefits Package Schemes: Comparative Analysis of Co-Payments for Reimbursable Medicines in European Countries," Applied Health Economics and Health Policy, Springer, vol. 17(6), pages 803-816, December.
    17. Hanna Koskinen & Elina Ahola & Leena Saastamoinen & Hennamari Mikkola & Jaana Martikainen, 2014. "The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland," Health Economics Review, Springer, vol. 4(1), pages 1-10, December.
    18. Ghislandi, Simone, 2011. "Competition and the Reference Pricing Scheme for pharmaceuticals," Journal of Health Economics, Elsevier, vol. 30(6), pages 1137-1149.
    19. Lagravinese, Raffaele & Paradiso, Massimo, 2012. "Corruption and health expenditure in Italy," MPRA Paper 43215, University Library of Munich, Germany.
    20. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    21. Iacocca, Kathleen & Mahar, Stephen & Daniel Wright, P., 2022. "Strategic horizontal integration for drug cost reduction in the pharmaceutical supply chain," Omega, Elsevier, vol. 108(C).
    22. Timothy Tyler Brown & Juan Pablo Atal, 2019. "How robust are reference pricing studies on outpatient medical procedures? Three different preprocessing techniques applied to difference‐in differences," Health Economics, John Wiley & Sons, Ltd., vol. 28(2), pages 280-298, February.
    23. Crea, Giovanni & Galizzi, Matteo M. & Linnosmaa, Ismo & Miraldo, Marisa, 2019. "Physician altruism and moral hazard: (no) evidence from Finnish national prescriptions data," LSE Research Online Documents on Economics 100301, London School of Economics and Political Science, LSE Library.
    24. Dominik J. Wettstein & Stefan Boes, 2019. "Effectiveness of National Pricing Policies for Patent-Protected Pharmaceuticals in the OECD: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 17(2), pages 143-162, April.
    25. Marion Aouad & Timothy T. Brown & Christopher M. Whaley, 2021. "Understanding the distributional impacts of health insurance reform: Evidence from a consumer cost‐sharing program," Health Economics, John Wiley & Sons, Ltd., vol. 30(11), pages 2780-2793, November.
    26. François Bocquet & Pascal Paubel & Isabelle Fusier & Anne-Laure Cordonnier & Martine Sinègre & Claude Le Pen, 2015. "Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 47-59, February.
    27. Livio Garattini & Katelijne Vooren, 2013. "Could co-payments on drugs help to make EU health care systems less open to political influence?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(5), pages 709-713, October.
    28. Hokkanen, Joni & Kangasharju, Aki & Linnosmaa, Ismo & Valtonen, Hannu, 2012. "Generic substitution policy, prices and market structure: evidence from a quasi-experiment in Finland," Working Papers 35, VATT Institute for Economic Research.
    29. François Bocquet & Pascal Paubel & Isabelle Fusier & Anne-Laure Cordonnier & Claude Pen & Martine Sinègre, 2014. "Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis," Applied Health Economics and Health Policy, Springer, vol. 12(3), pages 315-326, June.

  18. Miraldo, Marisa & Siciliani, Luigi & Street, Andrew, 2011. "Price adjustment in the hospital sector," Journal of Health Economics, Elsevier, vol. 30(1), pages 112-125, January.
    See citations under working paper version above.
  19. Galizzi, Matteo M. & Miraldo, Marisa, 2011. "The effects of hospitals' governance on optimal contracts: Bargaining vs. contracting," Journal of Health Economics, Elsevier, vol. 30(2), pages 408-424, March.

    Cited by:

    1. Ali Uyar & Cemil Kuzey & Merve Kilic & Abdullah S. Karaman, 2021. "Board structure, financial performance, corporate social responsibility performance, CSR committee, and CEO duality: Disentangling the connection in healthcare," Corporate Social Responsibility and Environmental Management, John Wiley & Sons, vol. 28(6), pages 1730-1748, November.
    2. De Luca, Giacomo & Lisi, Domenico & Martorana, Marco & Siciliani, Luigi, 2021. "Does higher Institutional Quality improve the Appropriateness of Healthcare Provision?," Journal of Public Economics, Elsevier, vol. 194(C).
    3. Diogo Cunha Ferreira & Rui Cunha Marques & Alexandre Morais Nunes, 2021. "Pay for performance in health care: a new best practice tariff-based tool using a log-linear piecewise frontier function and a dual–primal approach for unique solutions," Operational Research, Springer, vol. 21(3), pages 2101-2146, September.
    4. Simon B. Spika & Peter Zweifel, 2019. "Buying efficiency: optimal hospital payment in the presence of double upcoding," Health Economics Review, Springer, vol. 9(1), pages 1-14, December.
    5. Mauro Romano & Antonio Netti & Antonio Corvino & Marika Intenza, 2024. "Environmental innovation in healthcare industry: The moderating role of women on board in cost of debt," Corporate Social Responsibility and Environmental Management, John Wiley & Sons, vol. 31(3), pages 1921-1933, May.

  20. Street, Andrew & Sivey, Peter & Mason, Anne & Miraldo, Marisa & Siciliani, Luigi, 2010. "Are English treatment centres treating less complex patients?," Health Policy, Elsevier, vol. 94(2), pages 150-157, February.

    Cited by:

    1. Bjorvatn, Afsaneh, 2018. "Private or public hospital ownership: Does it really matter?," Social Science & Medicine, Elsevier, vol. 196(C), pages 166-174.
    2. Jason Sutherland & R. T. Crump & Nadya Repin & Erik Hellsten, 2013. "Paying for Hospital Services: A Hard Look at the Options," C.D. Howe Institute Commentary, C.D. Howe Institute, issue 378, April.
    3. Giuseppe Moscelli & Hugh Gravelle & Luigi Siciliani, 2016. "Market structure, patient choice and hospital quality for elective patients," Working Papers 139cherp, Centre for Health Economics, University of York.
    4. Pérotin, Virginie & Zamora, Bernarda & Reeves, Rachel & Bartlett, Will & Allen, Pauline, 2013. "Does hospital ownership affect patient experience? An investigation into public–private sector differences in England," Journal of Health Economics, Elsevier, vol. 32(3), pages 633-646.
    5. Zack Cooper & Stephen Gibbons & Matthew Skellern, 2016. "Does competition from private surgical centres improve public hospitals' performance? Evidence from the English National Health Service," CEP Discussion Papers dp1434, Centre for Economic Performance, LSE.
    6. L. Garattini & Marco Badinella Martini, 2023. "Modeling European health systems: a theoretical exercise," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(8), pages 1249-1252, November.
    7. Kim, Sun Jung & Park, Eun-Cheol & Jang, Sung In & Lee, Minjee & Kim, Tae Hyun, 2013. "An analysis of the inpatient charge and length of stay for patients with joint diseases in Korea: Specialty versus small general hospitals," Health Policy, Elsevier, vol. 113(1), pages 93-99.
    8. Elaine Kelly & George Stoye, 2020. "The Impacts of Private Hospital Entry on the Public Market for Elective Care in England," IFS Working Papers W20/1, Institute for Fiscal Studies.
    9. Anne Mason & Zeynep Or & Thomas Renaud & Andrew Street & Josselin Thuilliez & Padraic Ward & ON BEHALF OF THE EURODRG GROUP, 2012. "How Well Do Diagnosis‐Related Groups For Appendectomy Explain Variations In Resource Use? An Analysis Of Patient‐Level Data From 10 European Countries," Health Economics, John Wiley & Sons, Ltd., vol. 21(S2), pages 30-40, August.
    10. Heijink, Richard & Mosca, Ilaria & Westert, Gert, 2013. "Effects of regulated competition on key outcomes of care: Cataract surgeries in the Netherlands," Health Policy, Elsevier, vol. 113(1), pages 142-150.
    11. Cheng, Terence C. & Haisken-DeNew, John P. & Yong, Jongsay, 2015. "Cream skimming and hospital transfers in a mixed public-private system," Social Science & Medicine, Elsevier, vol. 132(C), pages 156-164.
    12. Adriana Castelli & Andrew Street & Rossella Verzulli & Padraic Ward, 2015. "Examining variations in hospital productivity in the English NHS," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(3), pages 243-254, April.
    13. Daidone, Silvio & Street, Andrew, 2013. "How much should be paid for specialised treatment?," Social Science & Medicine, Elsevier, vol. 84(C), pages 110-118.
    14. Giuseppe Moscelli & Hugh Gravelle & Luigi Siciliani, 2021. "Hospital competition and quality for non‐emergency patients in the English NHS," RAND Journal of Economics, RAND Corporation, vol. 52(2), pages 382-414, June.
    15. Luigi Siciliani & Peter Sivey & Andrew Street, 2011. "Differences in Length of Stay between Public Hospitals, Treatment Centres and Private Providers: Selection or Efficiency?," Melbourne Institute Working Paper Series wp2011n06, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
    16. Chris Bojke & Adriana Castelli & Mauro Laudicella & Andrew Street & Padraic Ward, 2010. "Regional variation in the productivity of the English National Health Service," Working Papers 057cherp, Centre for Health Economics, University of York.
    17. Luigi Siciliani & Peter Sivey & Andrew Street, 2013. "Differences In Length Of Stay For Hip Replacement Between Public Hospitals, Specialised Treatment Centres And Private Providers: Selection Or Efficiency?," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 234-242, February.

  21. Miraldo, Marisa, 2009. "Reference pricing and firms' pricing strategies," Journal of Health Economics, Elsevier, vol. 28(1), pages 176-197, January.

    Cited by:

    1. Herr, Annika & Suppliet, Moritz, 2012. "Pharmaceutical prices under regulation: Tiered co-payments and reference pricing in Germany," DICE Discussion Papers 48, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE).
    2. David Granlund & Miyase Koksal-Ayhan, 2015. "Parallel imports and a mandatory substitution reform: a kick or a muff for price competition in pharmaceuticals?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(9), pages 969-983, December.
    3. Gilad Sorek, 2015. "Competition and Product Choice in Option Demand Markets," Auburn Economics Working Paper Series auwp2015-11, Department of Economics, Auburn University.
    4. Geng, Difei & Saggi, Kamal, 2017. "International effects of national regulations: External reference pricing and price controls," Journal of International Economics, Elsevier, vol. 109(C), pages 68-84.
    5. Kaiser, Ulrich & Mendez, Susan J. & Rønde, Thomas, 2010. "Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark," ZEW Discussion Papers 10-062, ZEW - Leibniz Centre for European Economic Research.
    6. Paolo Buonanno & Matteo M. Galizzi, 2012. "Advocatus, et non Latro? Testing the Supplier-Induced Demand Hypothesis for the Italian Courts of Justice," Carlo Alberto Notebooks 250, Collegio Carlo Alberto.
    7. Kurt R. Brekke & Tor Helge Holmås & Odd Rune Straume, 2010. "Reference Pricing, Competition, and Pharmaceutical Expenditures: Theory and Evidence from a Natural Experiment," CESifo Working Paper Series 3258, CESifo.
    8. Timothy T. Brown & James C. Robinson, 2016. "Reference Pricing with Endogenous or Exogenous Payment Limits: Impacts on Insurer and Consumer Spending," Health Economics, John Wiley & Sons, Ltd., vol. 25(6), pages 740-749, June.
    9. Begoña Garcia Mariñoso & Izabela Jelovac & Pau Olivella, 2011. "External referencing and pharmaceutical price negotiation," Post-Print halshs-00303682, HAL.
    10. Granlund, David & Bergman, Mats A., 2018. "Price competition in pharmaceuticals – Evidence from 1303 Swedish markets," Journal of Health Economics, Elsevier, vol. 61(C), pages 1-12.
    11. Kurt R. Brekke & Chiara Canta & Odd Rune Straume, 2015. "Reference pricing with endogenous generic entry," NIPE Working Papers 2/2015, NIPE - Universidade do Minho.
    12. Ajay Bhaskarabhatla & Priyatam Anurag & Chirantan Chatterjee & Enrico Pennings, 2021. "How Does Regulation Impact Strategic Repositioning by Firms Across Submarkets? Evidence from the Indian Pharmaceutical Industry," Strategy Science, INFORMS, vol. 6(3), pages 209-227, September.
    13. Yesim Köksal, Miyase, 2009. "REFERENCE PRICING - Making Parallel Trade in Pharmaceuticals Work," Working Papers in Economics 367, University of Gothenburg, Department of Economics, revised 01 May 2011.
    14. Simone Ghislandi & Patrizio Armeni & Claudio Jommi, 2013. "The impact of generic reference pricing in Italy, a decade on," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 959-969, December.
    15. A. Cavaliere & G. Crea, 2022. "Brand premia driven by perceived vertical differentiation in markets with information disparity and optimistic consumers," Journal of Economics, Springer, vol. 135(3), pages 223-253, April.
    16. Charitini Stavropoulou & Tommaso Valletti, 2015. "Compulsory licensing and access to drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(1), pages 83-94, January.
    17. Granlund, David & Yesim Köksal, Miyase, 2011. "Parallel Imports and Mandatory Substitution Reform: A kick or a muff for price competition in pharmaceuticals," Working Papers in Economics 496, University of Gothenburg, Department of Economics.
    18. R. Rovbel L. & Р. Ровбель Л., 2018. "Анализ проблем и возможностей использования референтного ценообразования органами государственной власти и местного самоуправления в сфере закупок и жилищного строительства // Analyzing the Problems a," Управленческие науки // Management Science, ФГОБУВО Финансовый университет при Правительстве Российской Федерации // Financial University under The Government of Russian Federation, vol. 8(2), pages 44-51.
    19. F. Antoñanzas & C. A. Juárez-Castelló & R. Rodríguez-Ibeas, 2017. "Endogenous versus exogenous generic reference pricing for pharmaceuticals," International Journal of Health Economics and Management, Springer, vol. 17(4), pages 413-432, December.
    20. Julia Graf, 2014. "The effects of rebate contracts on the health care system," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(5), pages 477-487, June.
    21. Gregory J. Critchley & Gregory S. Zaric, 2019. "The impact of pharmaceutical marketing on market access, treatment coverage, pricing, and social welfare," Health Economics, John Wiley & Sons, Ltd., vol. 28(8), pages 1035-1051, August.
    22. Granlund, David & Köksal, Miyase Yesim, 2011. "Parallel Imports and Mandatory Substitution Reform - A Kick or A Muff for Price Competition in Pharmaceuticals?," HUI Working Papers 49, HUI Research.
    23. Ghislandi, Simone, 2011. "Competition and the Reference Pricing Scheme for pharmaceuticals," Journal of Health Economics, Elsevier, vol. 30(6), pages 1137-1149.
    24. Ricardo Gonçalves & Vasco Rodrigues & Hélder Vasconcelos, 2015. "Reference pricing in the presence of pseudo-generics," International Journal of Health Economics and Management, Springer, vol. 15(3), pages 281-305, September.
    25. Gilad Sorek, 2015. "Health Insurance and Competition in Health Care Markets," Auburn Economics Working Paper Series auwp2015-03, Department of Economics, Auburn University.
    26. Matteo Galizzi & Simone Ghislandi & Marisa Miraldo, 2011. "Effects of Reference Pricing in Pharmaceutical Markets," PharmacoEconomics, Springer, vol. 29(1), pages 17-33, January.
    27. Herr, Annika & Stühmeier, Torben & Wenzel, Tobias, 2014. "Reference pricing and cost-sharing: Theory and evidence on German off-patent drugs," VfS Annual Conference 2014 (Hamburg): Evidence-based Economic Policy 100556, Verein für Socialpolitik / German Economic Association.

  22. Mason, Anne & Street, Andrew & Miraldo, Marisa & Siciliani, Luigi, 2009. "Should prospective payments be differentiated for public and private healthcare providers?," Health Economics, Policy and Law, Cambridge University Press, vol. 4(4), pages 383-403, October.

    Cited by:

    1. Andrew Street & Conrad Kobel & Thomas Renaud & Josselin Thuilliez, 2012. "How well do diagnosis-related groups explain variations in costs or length of stay among patients and across hospitals? Methods for analysing routine patient data," Post-Print halshs-00719777, HAL.
    2. Matthias Vogl, 2012. "Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany," Health Economics Review, Springer, vol. 2(1), pages 1-12, December.
    3. Chris Bojke & Katja Grašič & Andrew Street, 2018. "How should hospital reimbursement be refined to support concentration of complex care services?," Health Economics, John Wiley & Sons, Ltd., vol. 27(1), pages 26-38, January.
    4. Laudicella, Mauro & Olsen, Kim Rose & Street, Andrew, 2010. "Examining cost variation across hospital departments-a two-stage multi-level approach using patient-level data," Social Science & Medicine, Elsevier, vol. 71(10), pages 1872-1881, November.
    5. Xidong Guo, 2024. "An analysis of a rural hospital's investment decision under different payment systems," Health Economics, John Wiley & Sons, Ltd., vol. 33(4), pages 714-747, April.

  23. Giorgia Marini & Marisa Miraldo & Rowena Jacobs & Maria Goddard, 2008. "Giving greater financial independence to hospitals—does it make a difference? The case of English NHS Trusts," Health Economics, John Wiley & Sons, Ltd., vol. 17(6), pages 751-775, June.

    Cited by:

    1. Giuseppe Moscelli & Hugh Gravelle & Luigi Siciliani, 2016. "Market structure, patient choice and hospital quality for elective patients," Working Papers 139cherp, Centre for Health Economics, University of York.
    2. James Gaughan & Nils Gutacker & Katja Grasic & Noemi Kreif & Luigi Siciliani & Andrew Street, 2018. "Paying for Efficiency: Incentivising same-day discharges in the English NHS," Working Papers 157cherp, Centre for Health Economics, University of York.
    3. Rossella Verzulli & Rowena Jacobs & Maria Goddard, 2011. "Do hospitals respond to greater autonomy? Evidence from the English NHS," Working Papers 064cherp, Centre for Health Economics, University of York.
    4. R. Verzulli & G. Fiorentini & M. Lippi Bruni & C. Ugolini, 2015. "Price Changes in Regulated Healthcare Markets: Do Public Hospitals Respond and How?," Working Papers wp1041, Dipartimento Scienze Economiche, Universita' di Bologna.
    5. Cheng, Terence C. & Haisken-DeNew, John P. & Yong, Jongsay, 2015. "Cream skimming and hospital transfers in a mixed public-private system," Social Science & Medicine, Elsevier, vol. 132(C), pages 156-164.
    6. Giuseppe Moscelli & Hugh Gravelle & Luigi Siciliani, 2021. "Hospital competition and quality for non‐emergency patients in the English NHS," RAND Journal of Economics, RAND Corporation, vol. 52(2), pages 382-414, June.
    7. Luigi Siciliani & Peter Sivey & Andrew Street, 2011. "Differences in Length of Stay between Public Hospitals, Treatment Centres and Private Providers: Selection or Efficiency?," Melbourne Institute Working Paper Series wp2011n06, Melbourne Institute of Applied Economic and Social Research, The University of Melbourne.
    8. Gravelle, Hugh & Santos, Rita & Siciliani, Luigi, 2014. "Does a hospital's quality depend on the quality of other hospitals? A spatial econometrics approach," Regional Science and Urban Economics, Elsevier, vol. 49(C), pages 203-216.
    9. J. Buckell & A. Smith & R. Longo & D. Holland, 2015. "Efficiency, heterogeneity and cost function analysis: empirical evidence from pathology services in the National Health Service in England," Applied Economics, Taylor & Francis Journals, vol. 47(31), pages 3311-3331, July.
    10. Brekke, Kurt R. & Siciliani, Luigi & Straume, Odd Rune, 2012. "Quality competition with profit constraints," Journal of Economic Behavior & Organization, Elsevier, vol. 84(2), pages 642-659.
    11. Giuseppe Moscelli & Hugh Gravelle & Luigi Siciliani, 2018. "Effects of Market Structure and Patient Choice on Hospital Quality for Planned Patients," School of Economics Discussion Papers 1118, School of Economics, University of Surrey.
    12. Moscelli, Giuseppe & Gravelle, Hugh & Siciliani, Luigi, 2023. "The effect of hospital choice and competition on inequalities in waiting times," Journal of Economic Behavior & Organization, Elsevier, vol. 205(C), pages 169-201.
    13. Luigi Siciliani & Peter Sivey & Andrew Street, 2013. "Differences In Length Of Stay For Hip Replacement Between Public Hospitals, Specialised Treatment Centres And Private Providers: Selection Or Efficiency?," Health Economics, John Wiley & Sons, Ltd., vol. 22(2), pages 234-242, February.
    14. Rossella Verzulli & Rowena Jacobs & Maria Goddard, 2018. "Autonomy and performance in the public sector: the experience of English NHS hospitals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 607-626, May.

Chapters

  1. Eliana Barrenho & Marisa Miraldo, 2018. "R&D Success in Pharmaceutical Markets: A Duration Model Approach," Contributions to Economic Analysis, in: Health Econometrics, volume 127, pages 201-233, Emerald Group Publishing Limited.

    Cited by:

    1. Gentilini, Arianna & Miraldo, Marisa, 2023. "The role of patient organisations in research and development: Evidence from rare diseases," Social Science & Medicine, Elsevier, vol. 338(C).

  2. Matteo M. Galizzi & Glenn W. Harrison & Marisa Miraldo, 2018. "Experimental Methods and Behavioral Insights in Health Economics: Estimating Risk and Time Preferences in Health," Contributions to Economic Analysis, in: Health Econometrics, volume 127, pages 1-21, Emerald Group Publishing Limited.

    Cited by:

    1. Thomas Meissner & Xavier Gassmann & Corinne Faure & Joachim Schleich, 2023. "Individual characteristics associated with risk and time preferences: A multi country representative survey," Journal of Risk and Uncertainty, Springer, vol. 66(1), pages 77-107, February.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.